NCT07293247ClinicalTrials.gov
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
Involved-Station, Intensity-Modulated Post-Operative Radiation Therapy (I²-PORT) for Resected Non-Small Cell Lung Cancer With Residual Mediastinal Adenopathy After Neoadjuvant Therapy (ypN2)
In breve
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining…
Fase 2164 partecipanti ricercati125 centri1 paese
Categorie
Registrato in 1 registro
- ClinicalTrials.govNCT07293247Apri questa scheda su ClinicalTrials.govSincronizzato 2 settimane fa
Uno studio può essere registrato in più registri. Lo mostriamo una volta sola e colleghiamo ogni scheda in nostro possesso.
Le informazioni sulla sperimentazione sono mostrate così come pubblicate dal registro, nella lingua originale.
Ti interessa questo studio?
Accedi oppure crea un account per registrare il tuo interesse e seguire questo studio.
How this study is set up
The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.
- Present: Registered before enrolment beganFirst posted 2025-12-19; recorded start 2026-10-14
- Present: Has a defined primary outcomeA primary outcome measure is listed in the record
- Present: The primary outcome states a time frameThe primary outcome measure records a time frame
- Present: Participants are randomly assignedAllocation is recorded as randomised
- Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
- Not stated: Open label (no blinding)Masking is recorded as none (open label)
- Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
- Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
- Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
- Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
- Present: Sponsor has 97 other studies in this databaseCounted from the lead sponsor named in the record (Alliance for Clinical Trials in Oncology)
- Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
- The record lists 1 condition.
- Lead sponsor type recorded as: other.
- Intervention regulatory context: investigational, within a phased regulatory pathway.
Trial stature
Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.
A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.
How this score is built
- Randomised allocation20/20
Participants are randomly allocated between arms
- Blinding0/20
Open-label
- Control arm15/15
Active-comparator control arm
- Primary-outcome specificity10/10
Named primary outcome with a defined time frame
- Endpoint type10/10
Mortality / MACE endpoint (hard clinical outcome)
- Multi-centre8/8
Multi-centre: 33 sites
- Data monitoring committee0/7
No data monitoring committee stated
- Prospective registration5/5
Registered before the study start date
- Protocol / SAP posted0/5
No protocol or SAP posted to the registry
A small study: 164 participants (target), run at 125 sites.
How this score is built
- Enrolment21/40
164 participants (target)
- Site count18/25
33 sites
- Country count0/15
Single country
- Planned duration10/10
Planned over about 69 months
- Sponsor scale7/10
Alliance for Clinical Trials in Oncology has led 96 trials in our corpus
We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.
How this score is built
- Investigator standing0/100
No investigator recorded in the registry for this trial
These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.
Sintesi
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-small cell lung cancer (NSCLC) who have remaining lymph node cancer after surgery. Radiation therapy uses high-energy X-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Intensity-modulated radiation therapy is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Chemotherapy drugs work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy may induce changes in the body's immune system and may interfere with the ability of tumor cells to grow and spread. Adding I²-PORT radiation therapy to standard therapy may be more effective than standard therapy alone in reducing the risk of cancer returning in those who have undergone surgery for NSCLC.
Patologie
- Lung Non-Small Cell Carcinoma
Idoneità
| Sesso | Tutti |
|---|---|
| Età | 18 Years – Nessun massimo |
| Volontari sani | No |
Idoneità come riportata nel registro
Idoneità in frasi semplici
I criteri di questa scheda non sono ancora stati suddivisi in affermazioni distinte. Il testo del registro qui sopra è completo ed è la versione autorevole.
Disegno dello studio
| Tipo di studio | Interventistico |
|---|---|
| Fase | Fase 2 |
| Assegnazione | Randomizzata |
| Modello di intervento | PARALLEL |
| Finalità principale | TREATMENT |
| Mascheramento | NONE (0) |
| Arruolamento | 164 partecipanti ricercati |
Sponsor e collaboratori
- Alliance for Clinical Trials in Oncology Sponsor
- National Cancer Institute (NCI) Collaboratori
Bracci e interventi
- Arm I (SOC chemotherapy/immunotherapy)ACTIVE_COMPARATOR
Patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
- Arm II (I²-PORT, SOC chemotherapy/immunotherapy)EXPERIMENTAL
Patients undergo I²-PORT QD Monday through Friday over 15-25 fractions over 5-6 weeks. Starting 1-42 days after completion of I²-PORT, patients receive SOC chemotherapy or immunotherapy on study. Treatment continues in the absence of disease progression or unacceptable toxicity. Patients also undergo CT and/or MRI, FDG-PET, and blood sample collection throughout the study.
Interventi
- Procedura Biospecimen Collection
Undergo blood sample collection
- Farmaco Chemotherapy
Receive standard of care chemotherapy
- Procedura Computed Tomography
Undergo CT
- Altro Fludeoxyglucose F-18
Undergo FDG PET scan
- Altro Immunotherapy
Receive standard of care immunotherapy
- Radiazioni Intensity-Modulated Radiation Therapy
Undergo I²-PORT
- Procedura Magnetic Resonance Imaging
Undergo MRI
Esiti misurati
Esito primario
Disease-free survival (DFS)
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. The median DFS for each treatment group will be estimated, and its 80% and 90% confidence intervals will be calculated using the Kaplan-Meier estimator. Additionally, the 24-month DFS rate for each treatment arm, along with its confidence intervals, will be calculated.
Orizzonte temporale Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
Esito primario
Incidence of late grade ≥ 3 cardiopulmonary toxicities
Will be assessed according to the Common Terminology Criteria for Adverse Events version 5.0. Will be estimated for each treatment group and the difference between the two treatment groups. The confidence intervals of the rate difference at 80% and 90% significance levels will be estimated using the Miettinen-Nurminen method.
Orizzonte temporale Between 3 and 24 months after protocol therapy
Esito secondario
5-year DFS
DFS will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1
Orizzonte temporale Time from the date of randomization to the date of earliest disease recurrence/progression or deaths of all causes, assessed up to 5 years
Esito secondario
2-year overall survival (OS)
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
Orizzonte temporale Time from the date of randomization to death from all causes, assessed up to 2 years
Esito secondario
5-year OS
Will be analyzed using the Kaplan-Meier methodology and compared between Arm 2 and Arm 1 using a log-rank test stratified by randomization factors. Multivariable Cox models will evaluate the treatment effect on survival time and its interaction with baseline covariates, including stage, pre-treatment, histology, and performance status.
Orizzonte temporale Time from the date of randomization to death from all causes, assessed up to 5 years Symptomatic skeletal event free survival (SSE-FS)
Esito secondario
Patient-reported symptoms
Will be assessed using Patient Reported Outcomes - Common Terminology Criteria for Adverse Events and will be evaluated for between-arm differences in proportions of patients with a maximum post-baseline score greater than 0 using Fisher's exact or chi-square test.
Orizzonte temporale up to 5 years
Date
| Data di inizio | 14 ottobre 2026 (stimata) |
|---|---|
| Conclusione primaria | 31 dicembre 2032 (stimata) |
| Conclusione | 1 marzo 2036 (stimata) |
| Prima pubblicazione | 19 dicembre 2025 (effettiva) |
| Ultimo aggiornamento | 3 novembre 2026 |
| Risultati pubblicati | Non indicato nella scheda del registro |
| Stato verificato l'ultima volta | novembre 2026 |
«Effettiva» significa che l'evento è avvenuto. «Stimata» significa che lo sponsor lo prevede. Le due cose non sono equivalenti.
Centri
121 centri stanno reclutando
United States
| Struttura | Città | Stato o regione | Stato |
|---|---|---|---|
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor | Ann Arbor | Michigan | In reclutamento |
| Northwest Wisconsin Cancer Center | Ashland | Wisconsin | In reclutamento |
| Duluth Clinic Ashland | Ashland | Wisconsin | In reclutamento |
| Mount Sinai Comprehensive Cancer Center at Aventura | Aventura | Florida | In reclutamento |
| Memorial Sloan Kettering Basking Ridge | Basking Ridge | New Jersey | In reclutamento |
| MaineHealth Coastal Cancer Treatment Center | Bath | Maine | In reclutamento |
| UPMC-Heritage Valley Health System Beaver | Beaver | Pennsylvania | In reclutamento |
| Sanford Joe Lueken Cancer Center | Bemidji | Minnesota | In reclutamento |
| Sanford Bismarck Medical Center | Bismarck | North Dakota | In reclutamento |
| Illinois CancerCare-Bloomington | Bloomington | Illinois | In reclutamento |
| OSF Saint Joseph Medical Center | Bloomington | Illinois | In reclutamento |
| Essentia Health Saint Joseph's Medical Center | Brainerd | Minnesota | In reclutamento |
| Trinity Health IHA Medical Group Hematology Oncology - Brighton | Brighton | Michigan | In reclutamento |
| Trinity Health Medical Center - Brighton | Brighton | Michigan | In reclutamento |
| MaineHealth Cancer Care and IV Therapy - Brunswick | Brunswick | Maine | In reclutamento |
| Trinity Health Medical Center - Canton | Canton | Michigan | In reclutamento |
| Trinity Health IHA Medical Group Hematology Oncology - Canton | Canton | Michigan | In reclutamento |
| Illinois CancerCare-Canton | Canton | Illinois | In reclutamento |
| Saint Francis Medical Center | Cape Girardeau | Missouri | In reclutamento |
| Carlisle Regional Cancer Center | Carlisle | Pennsylvania | In reclutamento |
| Illinois CancerCare-Carthage | Carthage | Illinois | In reclutamento |
| UNC Lineberger Comprehensive Cancer Center | Chapel Hill | North Carolina | In reclutamento |
| Medical University of South Carolina | Charleston | South Carolina | In reclutamento |
| Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital | Chelsea | Michigan | In reclutamento |
| Chelsea Hospital | Chelsea | Michigan | In reclutamento |
| Rush MD Anderson Cancer Center | Chicago | Illinois | In reclutamento |
| Clackamas Radiation Oncology Center | Clackamas | Oregon | In reclutamento |
| Baptist Memorial Hospital and Cancer Center-Collierville | Collierville | Tennessee | In reclutamento |
| Ohio State University Comprehensive Cancer Center | Columbus | Ohio | In reclutamento |
| Memorial Sloan Kettering Commack | Commack | New York | In reclutamento |
| Cancer Care Specialists of Illinois - Decatur | Decatur | Illinois | In reclutamento |
| Decatur Memorial Hospital | Decatur | Illinois | In reclutamento |
| Essentia Health - Deer River Clinic | Deer River | Minnesota | In reclutamento |
| Essentia Health Cancer Center | Duluth | Minnesota | In reclutamento |
| Miller-Dwan Hospital | Duluth | Minnesota | In reclutamento |
| Essentia Health Saint Mary's Medical Center | Duluth | Minnesota | In reclutamento |
| Duke University Medical Center | Durham | North Carolina | In reclutamento |
| Marshfield Medical Center-EC Cancer Center | Eau Claire | Wisconsin | In reclutamento |
| UPMC Hillman Cancer Center Erie | Erie | Pennsylvania | In reclutamento |
| Illinois CancerCare-Eureka | Eureka | Illinois | In reclutamento |
| Sanford Roger Maris Cancer Center | Fargo | North Dakota | In reclutamento |
| Sanford Broadway Medical Center | Fargo | North Dakota | In reclutamento |
| Parkland Health Center - Farmington | Farmington | Missouri | Sospeso |
| UPMC Cancer Center at UPMC Horizon | Farrell | Pennsylvania | In reclutamento |
| Illinois CancerCare-Galesburg | Galesburg | Illinois | In reclutamento |
| UPMC Cancer Centers - Arnold Palmer Pavilion | Greensburg | Pennsylvania | In reclutamento |
| UPMC Pinnacle Cancer Center/Community Osteopathic Campus | Harrisburg | Pennsylvania | In reclutamento |
| Memorial Sloan Kettering Westchester | Harrison | New York | In reclutamento |
| Essentia Health-Hayward Clinic | Hayward | Wisconsin | In reclutamento |
| Essentia Health Hibbing Clinic | Hibbing | Minnesota | In reclutamento |
Nella scheda del registro sono indicati altri 75 centri.
Documenti dello studio
In questa scheda del registro non sono collegati documenti.
Modifiche nel tempo
- 3 novembre 2026
Centro aggiunto
14 sites added (125 total)
111125
- 19 ottobre 2026
Data di conclusione posticipata
Primary completion delayed 1461 days
2028-12-312032-12-31
- 2 ottobre 2026
Centro aggiunto
14 sites added (111 total)
97111
- 2 settembre 2026
Centro aggiunto
23 sites added (97 total)
7497
- 5 agosto 2026
Centro aggiunto
41 sites added (74 total)
3374